精準醫療-醫療服務-樂普產品

樂普基因: 樂普基因在保持全資子公司北京愛普益醫學檢驗中心現有的生化、免疫、微生物、血液病、遺傳代謝和細胞組織病理的優勢前提下，借助二代基因測序平臺重點發展心血管高通量基因測序、無創產前篩查基因檢測（NIPT）和腫瘤基因測序服務，同時聯合北京樂普醫療科技有限責任公司熒光定量PCR技術優勢積極開展心血管個體化用藥相關的分子診斷試劑的研發、和銷售，從而構建一個以分子診斷和高通量測序為基礎的涵蓋研發、銷售和第三方醫學檢驗服務的閉環系統。
在心血管基因和腫瘤測序方面，公司與美國休斯敦醫學中心合作開展心血管疾病易感基因檢測，涵蓋心肌病、遺傳性心律失常、主動脈病、先天性心臟病、家族性高膽固醇血癥、結構性心臟疾病等心血管疾病；同時開展腫瘤易感基因檢測及用藥指導、新生兒遺傳代謝疾病基因、乳腺癌、糖尿病等易感基因的檢測項目；在分子診斷試劑研發銷售方面，與樂普醫療全資子公司北京樂普醫療科技有限責任公司已經聯合開發了心血管個體化用藥分子診斷試劑（CYP2C19、CYP2C9、VKORC1、ALDH2），由樂普基因獨家銷售。

愛普益醫學檢驗中心: 北京愛普益醫學檢驗中心是北京市衛生局批準成立的省級醫學獨立實驗室，創立于2007年，是一家專業從事醫學檢驗、醫學病理及科研服務等以第三方健康檢驗為主的科技服務型企業。

美國Quanterix: We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. Click on one of the therapeutic category icons below to learn how our revolutionary technology is helping researchers advance the science of precision health.
Kevin joined Quanterix in 2014 and serves as the Chief Executive Officer and Executive Chairman. While at Quanterix, Kevin has led the Company to achieve significant success and growth, recently securing a $46 million capital raise that elevated the Company’s valuation to ten times its revenue. With over 25 years of experience in the life sciences space, he has dedicated his career to transforming healthcare into personalized medicine, and has a proven track record of